The FDA has placed a partial hold on clinical studies of CTI BioPharma Corp.’s (CTIC) Pacritinib, its lead drug candidate for primary myelofibrosis, due to excess mortality and other adverse events in a pivotal trial.
Forex – financial instrument.Forex news
The FDA has placed a partial hold on clinical studies of CTI BioPharma Corp.’s (CTIC) Pacritinib, its lead drug candidate for primary myelofibrosis, due to excess mortality and other adverse events in a pivotal trial.